Janet Wozniak, MD
Associate Chief, Quality and Safety, Department of Psychiatry
Director, Child and Adolescent Outpatient Service
Director, Pediatric Bipolar Disorder Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Dr. Janet Wozniak received her undergraduate degree from Harvard College where she graduated magna cum laude. During her medical school training at Cornell University Medical College, she earned a SmithKline Beckman Medical Perspectives Award for Outstanding Medical Students.
Dr. Wozniak completed her adult and child psychiatry training at Massachusetts General Hospital. She has since received an Eli Lilly Pilot Research Award, the Elaine Schlosser Lewis Award and Claflin Distinguished Scholar Award. She is the Director of the Pediatric Bipolar Disorder Research Program and has received research funding from the National Institute of Mental Health, the Stanley Foundation, the National Alliance for Research in Schizophrenia and Depression, and the Heinz C. Prechter Fund for Manic Depression.
Dr. Wozniak's research focuses on the characteristics, longitudinal course and treatment of pediatric bipolar disorder. She has addressed the frequent occurrence of pediatric bipolar disorder and its atypical presentation, and documented the high rates of comorbidity of pediatric bipolar disorder with other conditions such as attention deficit/hyperactivity disorder, conduct disorder and anxiety disorders, as well as the frequency of occurrence of these disorders within families. Treatment studies include an open label trial of omega-3 fatty acids (fish oil) for mania in children and the use of topiramate to offset weight gain associated with olanzapine treatment of children with bipolar disorder.
Dr. Wozniak regularly presents her work at four different Harvard Continuing Medical Education (CME) courses: Psychopharmacology, Pediatric Psychopharmacology, ADHD Throughout the Life Span, and Treating the Aggressive Child and Adolescent. She lectures every year on the diagnosis and treatment of child and adolescent bipolar disorder to the psychiatry fellows as well as the child and adolescent psychiatry fellows. She directly supervises the child and adolescent psychiatry fellows on their pediatric psychopharmacology cases.
Dr. Wozniak is a member of the Professional Advisory Council of the Child and Adolescent Bipolar Foundation, a member of the Scientific Advisory Board of the STEP (Support, Treat, Educate, Prevent) Foundation for Bipolar children and adolescents and a member of the Scientific Advisory Board of the Ryan Licht Sang Biplolar Foundation. She is a past member of the Program Committee of the American Academy of Child and Adolescent Psychiatry, as well as a past member of the New Research Committee reviewing submissions to the annual meeting. Dr. Wozniak presents widely at national meetings devoted to psychiatric research including the American Psychiatric Association and the Association of Biological Psychiatry.
Dr. Wozniak's 1995 paper on childhood mania is one of the ten most cited papers ever to be published in the Journal of the American Academy of Child and Adolescent Psychiatry. Widely regarded as a national expert on the topic of pediatric bipolar disorder and attention deficit/hyperactivity disorder, Dr. Wozniak is the author of dozens of scientific articles, and she cares for hundreds of children and adolescents with these conditions in her clinical practice at the Massachusetts General Hospital. She is a co-author of the recently published book for parents, “Is Your Child Bipolar?”
Financial relationships
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Johnson and Johnson; PfizerTopic:Research SupportDate added:01/25/2022Date updated:11/05/2022
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Bantam BooksTopic:Royalties (Author)Date added:01/25/2022Date updated:11/05/2022
-
Attribution:Spouse or PartnerType of financial relationship:Professional ServicesIneligible company:Emalex; Noctrix; CVSTopic:ConsultationDate added:01/25/2022Date updated:11/05/2022